QUILT-3.088: NANT Pancreatic Cancer Vaccine
NCT03563144 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2025-02-21
Summary
QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients with Metastatic Pancreatic Cancer.
Conditions
Interventions
- DRUG
-
Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.
- DRUG
-
NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.
- DRUG
-
Aldoxorubicin HCl
Albumin-binding prodrug of doxorubicin HCl
- BIOLOGICAL
-
ALT-803
Recombinant human super agonist interleukin-15 (IL-15) complex
- BIOLOGICAL
-
ETBX-011
Ad5 \[E1-, E2b-\]-CEA
- BIOLOGICAL
-
ETBX-021
Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
- BIOLOGICAL
-
ETBX-051
Ad5 \[E1-, E2b-\]-Brachyury vaccine
- BIOLOGICAL
-
ETBX-061
Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
- BIOLOGICAL
-
GI-4000
Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
- BIOLOGICAL
-
GI-6207
CEA yeast vaccine
- BIOLOGICAL
-
GI-6301
Brachyury yeast vaccine
- BIOLOGICAL
-
haNK
NK-92 \[CD16.158V, ER IL-2\]
- DRUG
-
Avelumab
Avelumab
- DRUG
-
Bevacizumab
- DRUG
-
Capecitabine
- DRUG
-
2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
- DRUG
-
5-fluoro-2,4 (1H,3H)-pyrimidinedione
- DRUG
-
L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
- DRUG
-
Oxaliplatin
Sponsors & Collaborators
-
ImmunityBio, Inc.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-08-31
- Primary Completion
- 2019-12-30
- Completion
- 2022-02-09
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
NCT03197571 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
NCT03175666 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
NCT03387085 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
NCT03647423 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
NCT03127098 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NCT03552718 ·Status: COMPLETED ·Phase: PHASE1
-
Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
NCT00683085 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
NCT05098210 ·Status: RECRUITING ·Phase: PHASE1
-
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
NCT00085189 ·Status: COMPLETED ·Phase: PHASE2
-
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
NCT03809624 ·Status: TERMINATED ·Phase: PHASE1
-
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
NCT03853317 ·Status: TERMINATED ·Phase: PHASE2
-
Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors
NCT06614140 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
NCT03645928 ·Status: TERMINATED ·Phase: PHASE2
-
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
NCT01191684 ·Status: COMPLETED ·Phase: PHASE1
-
Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00334776 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
NCT04853017 ·Status: COMPLETED ·Phase: PHASE1
-
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
NCT03610490 ·Status: TERMINATED ·Phase: PHASE2
-
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
NCT03684785 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02834013 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)
NCT02465957 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
NCT03295942 ·Status: TERMINATED ·Phase: PHASE1
-
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
NCT04111172 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
NCT05741242 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.
NCT02678741 ·Status: COMPLETED ·Phase: PHASE1/PHASE2